Q2 2025 10X Genomics Inc Earnings Call Transcript
Key Points
- 10x Genomics Inc (TXG) reported a total revenue of $173 million for Q2 2025, with a favorable settlement in patent litigation contributing $68 million.
- The company increased its cash balance by $20 million during the quarter, excluding settlement-related payments.
- Strong performance in China contributed positively to the quarter's results, driven by purchasing dynamics related to tariffs.
- Chromium reaction volumes grew year-over-year and sequentially, indicating increasing demand for single-cell solutions.
- The company announced the acquisition of Scale Biosciences, which is expected to enhance its single-cell analysis capabilities and broaden access to these technologies.
- The academic funding landscape remains challenging, with shifting policies and weaker grant disbursements affecting customer spending.
- Total consumables revenue was down 1% year-over-year, with Chromium consumables revenue specifically down 9%.
- Total instrument revenue decreased by 39%, with Chromium instrument revenue down 35% due to lower average selling prices.
- The US academic and government funding landscape has not shown meaningful improvement, leading to conservative spending and capital equipment challenges.
- The company expects continued cautious customer spending behavior and ongoing capital equipment spending constraints in the near term.
Hello and thank you for standing by. My name is Tiffany, and I will be your conference operator today. At this time, I would like to welcome everyone to the 10X Genomics second-quarter 2025 earnings conference call. (Operator Instructions) I would now like to turn the call over to Cassie Corneau, Investor Relations and Strategic Finance. Cassie, please go ahead.
Thank you, and good afternoon, everyone. Earlier today, 10x Genomics released financial results for the second-quarter ended June 30, 2025. If you have not received this news release or would like to be added to the company's distribution list, please send an email to [email protected].
An archived webcast of this call will be available on the Investor tab of the company's website 10xgenomics.com, for at least 45 days following this call.
Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
